What is Zolgensma™?
Zolgensma, previously known as AVXS-101, is a gene replacement therapy developed to treat the genetic root cause of spinal muscular atrophy (SMA) type 1 in pediatric patients. The treatment was recently approved by the FDA as a single-dose intravenous treatment for infants.
In clinical trials, this one-time treatment has proven effective for the children and families affected by this life-threatening genetic disorder. Children’s Health is one of a few select locations in the U.S. able to provide this gene replacement therapy.
How can my child receive this treatment?
To receive Zolgensma, your child must first be seen in our Neurology clinic to determine if the treatment is appropriate.
Children’s Health is not able to administer Zolgensma to patients unless their health insurer has established coverage guidelines. We also cannot begin the process for authorization until your insurance carrier has issued guidelines. Once your Neurology Provider has determined Zolgensma treatment is appropriate, you will be contacted by our Managed Care team.
- As of today, we are not aware of insurers with established coverage guidelines for Zolgensma, but we have been in contact with major health insurance carriers and are hopeful that guidelines will be released soon.
- We encourage you to contact your insurance company and ask the status of their coverage guidelines.
- If your insurance plan is through an employer, we suggest you contact your employer’s HR personnel and ask them to also advocate for your child with contacts they may have at your insurance provider.
We know this can be a frustrating process as insurance guidelines are created. Children’s Health will continue to provide updated information to support our patient families in their efforts toward receiving Zolgensma.
If you have further questions after speaking with your insurance company, please contact our Managed Care team via email at firstname.lastname@example.org.